A Changing Paradigm in the Study and Adoption of Emerging Health Care Technologies: Coverage With Evidence Development

References 

1. Wallner P, Konski A. Significance of end-point selection in the assessment of emerging technologies. Oncology. 2007;21(suppl):32
2. Franklin GM, Wickizer TM, Fulton-Kehoe D, et al. Policy-relevant research: when does it matter?. NeuroRx. 2004;1:356–362
   • MEDLINE
   • CrossRef
3. Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;23:425–432
4. Tunis SR, Chalkidou K. Coverage with evidence development: a very good beginning, but much to be done. Int J Technol Assess Health Care. 2007;23:432–435
5. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's “coverage with evidence development.”. Health Aff. 2006;25:1218–1230
6. Pearson SD, Sabin JE, Emmanuel EJ. Medical necessity, coverage decisions, and medical policy. In: No margin, no mission: health care organizations and the quest for ethical excellence. New York: Oxford University Press; 2003;p. 69–71
7. Daniels N, Sabin JE. Last chance therapies and managed care: pluralism, fair procedures, and legitimacy. Hastings Ctr Rep. 1998;28:27–41
8. Garber AM. Evidence-based coverage policy. Health Aff. 2001;20:62–82
9. Centers for Medicare and Medicaid Services. National coverage determinations with data collection as a condition of coverage: coverage with evidence development. https://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8Accessed March 3, 2008
10. Cooksey D. A review of UK health research funding. http://www.hm-treasury.gov.uk/media/4/A/pbr06_cooksey_final_report_636.pdf
11. Carino T, Sheingold S, Tunis S. Using clinical trials as a condition of coverage: lessons from the national emphysema treatment trial. Clinical Trials. 2004;1:108–114
12. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–2073
    • CrossRef
13. Kolata G. Medicare says it will pay, but patients say “no thanks” (The New York Times). March 3 2006;
14. Tunis SR, Kang JL. Improvements in Medicare coverage of new technology. Health Aff. 2001;20:83–85
15. Centers for Medicare and Medicaid Services. Decision memo for pelvic floor electrical stimulation for urinary incontinence (CAG-00021N). http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=61Accessed March 3, 2008
16. US Food and Drug Administration. Implementation of the FDA/HCFA interagency agreement regarding reimbursement categorization of investigational devices (D95-2). http://www.fda.gov/cdrh/d952.htmlAccessed March 3, 2008
17. Centers for Medicare and Medicaid Services. Decision memo for percutaneous transluminal angioplasty (PTA) of the carotid artery concurrent with stenting (CAG-00085N). http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=62Accessed March 3, 2008
18. Centers for Medicare and Medicaid Services. Decision memo for positron emission tomography (FDG) for Alzheimer's disease/dementia. http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=64Accessed March 3, 2008
19. Matchar DM. Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia (Task Order 7). http://www.cms.gov/coverage/download/id64.pdfAccessed March 3, 2008
20. Weiss R. Medicare to cover cardiac device (The Washington Post). 2005;January 20
21. Kadish A. Prophylactic defibrillator implantation—toward an evidence-based approach. N Engl J Med. 2005;352:285–287
    • CrossRef
22. McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med. 2005;352:222–224
    • CrossRef
23. Gray BH, Gusmano MK, Collins SR. AHCPR and the changing politics of health services research. Health Aff (Millwood). 2003;3(suppl):283–307
24. Pearson SD, Miller FG, Emanuel EJ. Medicare's requirement for research participation as a condition of coverage: is it ethical?. JAMA. 2006;296:988–991
    • CrossRef
25. Bagley GP, Maxwell R. Linking Medicare coverage to research participation: reasonable and necessary?. http://wvifw.medicarerxguide.com/MDRG/2005/200306_BagleyWLPwhitepaper.pdfAccessed March 3, 2008